PURPOSE: Stage III designation in NWTS-5 (National Wilms Tumor Study-5) was determined by four pathologic criteria: positive lymph nodes (LNs), peritoneal implants, residual disease, and tumor rupture. The objective of this study was to determine the prognostic significance of each of the stage III criteria. PATIENTS AND METHODS: Children with stage III Wilms tumor (WT) treated in NWTS-5 were assessed for event-free (EFS) and overall survival (OS). Sites of relapse and molecular status of tumors are reported. EFS and OS are reported 8 years after diagnosis. RESULTS: There were 569 patients with local stage III favorable-histology (FH) WT in this analysis, of whom 109 had overall stage IV disease. LN involvement alone was the most frequent criterion for stage III designation (38%), followed by microscopic residual disease alone (20%), microscopic residual disease and LN involvement (14%), and spill or soilage alone (9%). The 8-year EFS and OS estimates for all patients with local stage III FHWT were 82% and 91%, respectively. Multivariate analysis demonstrated that both LN involvement (relative risk, 1.89; P = .005) and microscopic residual disease (relative risk, 1.87; P = .007) were predictive of EFS, and OS results were similar. There was no apparent difference in pattern of relapse according to stage III subtype. The rate of loss of heterozygosity was higher (6%) for those with positive LNs than for those without (2%; P = .05). CONCLUSION: LN involvement and microscopic residual are the stage III criteria highly predictive of EFS and OS for patients with stage III FHWT. It is possible that in future studies, patients with different stage III criteria may receive different therapies.
PURPOSE: Stage III designation in NWTS-5 (National Wilms Tumor Study-5) was determined by four pathologic criteria: positive lymph nodes (LNs), peritoneal implants, residual disease, and tumor rupture. The objective of this study was to determine the prognostic significance of each of the stage III criteria. PATIENTS AND METHODS: Children with stage III Wilms tumor (WT) treated in NWTS-5 were assessed for event-free (EFS) and overall survival (OS). Sites of relapse and molecular status of tumors are reported. EFS and OS are reported 8 years after diagnosis. RESULTS: There were 569 patients with local stage III favorable-histology (FH) WT in this analysis, of whom 109 had overall stage IV disease. LN involvement alone was the most frequent criterion for stage III designation (38%), followed by microscopic residual disease alone (20%), microscopic residual disease and LN involvement (14%), and spill or soilage alone (9%). The 8-year EFS and OS estimates for all patients with local stage III FHWT were 82% and 91%, respectively. Multivariate analysis demonstrated that both LN involvement (relative risk, 1.89; P = .005) and microscopic residual disease (relative risk, 1.87; P = .007) were predictive of EFS, and OS results were similar. There was no apparent difference in pattern of relapse according to stage III subtype. The rate of loss of heterozygosity was higher (6%) for those with positive LNs than for those without (2%; P = .05). CONCLUSION: LN involvement and microscopic residual are the stage III criteria highly predictive of EFS and OS for patients with stage III FHWT. It is possible that in future studies, patients with different stage III criteria may receive different therapies.
Authors: Daniel M Green; Yevgeny A Grigoriev; Bin Nan; Janice R Takashima; Pat A Norkool; Giulio J D'Angio; Norman E Breslow Journal: J Clin Oncol Date: 2003-06-15 Impact factor: 44.544
Authors: Geetika Khanna; Nancy Rosen; James R Anderson; Peter F Ehrlich; Jeffrey S Dome; Kenneth W Gow; Elizabeth Perlman; Douglas Barnhart; Kathryn Karolczuk; Paul Grundy Journal: Pediatr Blood Cancer Date: 2011-06-14 Impact factor: 3.167
Authors: D M Green; J B Beckwith; N E Breslow; P Faria; J Moksness; J Z Finklestein; P Grundy; P R Thomas; T Kim; S Shochat Journal: J Clin Oncol Date: 1994-10 Impact factor: 44.544
Authors: D M Green; N E Breslow; J B Beckwith; M L Ritchey; R C Shamberger; G M Haase; G J D'Angio; E Perlman; M Donaldson; P E Grundy; R Weetman; M J Coppes; M Malogolowkin; P Shearer; P Coccia; M Kletzel; P R Thomas; R Macklis; G Tomlinson; V Huff; R Newbury; D Weeks Journal: J Clin Oncol Date: 2001-09-01 Impact factor: 44.544
Authors: Norman E Breslow; San-San Ou; J Bruce Beckwith; Gerald M Haase; John A Kalapurakal; Michael L Ritchey; Robert C Shamberger; Patrick R M Thomas; Giulio J D'Angio; Daniel M Green Journal: Cancer Date: 2004-09-01 Impact factor: 6.860
Authors: Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger Journal: Ann Surg Date: 2017-04 Impact factor: 12.969
Authors: Sabah Servaes; Geetika Khanna; Arlene Naranjo; James I Geller; Peter F Ehrlich; Kenneth W Gow; Elizabeth J Perlman; Jeffrey S Dome; Eric Gratias; Elizabeth A Mullen Journal: Pediatr Radiol Date: 2014-08-19
Authors: Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome Journal: J Clin Oncol Date: 2017-12-06 Impact factor: 44.544
Authors: Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Jonathan P Walker; Jared S Johnson; Megan M Eguchi; Amanda F Saltzman; Myles Cockburn; Nicholas G Cost Journal: J Pediatr Urol Date: 2019-11-06 Impact factor: 1.830
Authors: Peter F Ehrlich; Thomas E Hamilton; Kenneth Gow; Douglas Barnhart; Fernando Ferrer; Jessica Kandel; Richard Glick; Roshni Dasgupta; Arlene Naranjo; Ying He; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Jeffrey S Dome; James Geller; Elizabeth Mullen Journal: Pediatr Blood Cancer Date: 2016-05-27 Impact factor: 3.167